{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:48:36Z","timestamp":1786373316557,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.2215\/cjn.0000000000000055","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T17:26:55Z","timestamp":1674840415000},"page":"154-156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?"],"prefix":"10.2215","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-8522","authenticated-orcid":false,"given":"Marie C.","family":"Hogan","sequence":"first","affiliation":[{"name":"Division of Nephrology & Hypertension, Mayo Clinic College of Medicine and Science, Rochester, Minnesota"},{"name":"Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic College of Medicine and Science, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana V.","family":"Masyuk","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota"},{"name":"Center for Basic Research in Digestive Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"5","key":"B2-20241015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.18773\/austprescr.2022.052","article-title":"Drug management of autosomal dominant polycystic kidney disease","volume":"45","author":"Theivendran","year":"2022","journal-title":"Aust Prescr."},{"issue":"1","key":"B3-20241015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B4-20241015","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B5-20241015","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-022-03353-8","article-title":"Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis","author":"Lu","year":"2022","journal-title":"Int Urol Nephrol."},{"issue":"13","key":"B6-20241015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/1535370218803893","article-title":"The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease","volume":"243","author":"Lin","year":"2018","journal-title":"Exp Biol Med (Maywood)."},{"issue":"8","key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","article-title":"Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease","volume":"90","author":"Hogan","year":"2015","journal-title":"Mayo Clin Proc."},{"issue":"8","key":"B8-20241015","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B9-20241015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B10-20241015","first-page":"223","article-title":"Effects of octreotide\u2013long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial","volume":"18","author":"Trillini","year":"2023","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000000000055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:43Z","timestamp":1786369483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000000000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000000000055","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]}}}